search
Back to results

High Flow Oxygen During Operative Hysteroscopy. (HOPE)

Primary Purpose

Endometrium; Hypertrophy, Cervix, Anesthesia, Apnea, Postanesthetic

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE).
LMA
Sponsored by
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Endometrium; Hypertrophy, Cervix focused on measuring High flow nasal cannula Oxygen, Procedural sedation, Apnoeic ventilation, Operative hysteroscopy, THRIVE

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients undergoing operative hysteroscopy
  • ASA I-II.

Exclusion Criteria:

  • BMI > 30,
  • pregnancy,
  • cardiac arrhythmia,
  • high risk of aspiration,
  • neuromuscular disease,
  • patient refusal.

Sites / Locations

  • IRCCS Fondazione Policlinico A. Gemelli

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

THRIVE

Control

Arm Description

Ventilatory management during surgery provided by transnasal humidified rapid-insufflation ventilatory exchange.

Ventilatory management during surgery provided by mechanical ventilation through laringeal mask

Outcomes

Primary Outcome Measures

Rate of success of ventilation with THRIVE.
Comparison of the rate of success in airways management with the THRIVE system versus positive pressure ventilation by laryngeal mask. The failure of the method will be defined as a CO2 value measured by transcutaneous monitor (Radiometer) > 65 mmHg AND/OR a peripheral O2 saturation measured by pulse oximeter < 94%.

Secondary Outcome Measures

Airway related complications.
Comparison of percentage of patients requiring airway manipulations (nasal cannula, manual ventilation, laryngeal mask ventilation, tracheal intubation) by the anesthesiologist in the two groups
Postoperative complications - 1
Comparison of percentage of patients suffering from cough, sore throat, dysphagia, dysphonia, laryngospasm, oxygen desaturation (defined as SpO2<94%).
Postoperative complications - 2
Comparison of incidence of dyspnoea (measured with Borg dyspnoea score: 0= no dyspnoea, 10= maximal dyspnoea) in the two groups.
Postoperative complications - 3
Comparison of incidence of discomfort (measured with Visual Analogue Scale: 0= no discomfort, 10= maximal discomfort) in the two groups.

Full Information

First Posted
September 15, 2022
Last Updated
September 15, 2023
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
search

1. Study Identification

Unique Protocol Identification Number
NCT05550584
Brief Title
High Flow Oxygen During Operative Hysteroscopy.
Acronym
HOPE
Official Title
High Flow Oxygen During ProcEdural Sedation for Operative Hysteroscopy: a Randomized Controlled Trial - HOPE Study.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
June 17, 2022 (Actual)
Primary Completion Date
October 1, 2022 (Actual)
Study Completion Date
May 1, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
High-flow nasal cannula (HFNC) oxygen therapy represents an open circuit ventilation system that uses flows up to 70 L/min of 100% oxygen through the Optiflow THRIVETM device (Fisher and Paykel Healthcare Ltd, Auckland, New Zealand). Compared to conventional oxygen therapy systems, the heating and humidification of the flows facilitate tolerability by the patient, allow to reach higher and more stable inspiratory fractions of oxygen, produce a flow-dependent effect of continuous positive airway pressure and by reducing dead space, have the potential to increase alveolar volume and improve gas exchanges. The use of HFNC is increased in anesthesia as the only airways management technique during short-term procedures under procedural sedation or general anesthesia. Operative hysteroscopy is a short-term procedure (<30 minutes), usually performed in a day-hospital regimen, under procedural sedation. In case of apnea and/or hypoventilation, or for long and complex hysteroscopic procedures, the patient can be ventilated through facial or laryngeal masks. The primary objective of this prospective randomized controlled trial is to compare the rate of success of ventilation using the THRIVE device to laryngeal mask ventilation during operative hysteroscopies under procedural sedation. Secondary objectives will be the comparison of the percentage of complications in terms of inability to manage the airways, episodes of hypotension, cardiac arrhythmias, post-operative nausea and vomiting, degree of dyspnea and comfort of the patient in the Post-Anesthesia Care Unit between the two methods.
Detailed Description
High-flow nasal cannula (HFNC) oxygen therapy represents an open circuit ventilation system that uses flows up to 70 L/min of 100% oxygen through Optiflow THRIVETM (transnasal humidified rapid-insufflation ventilatory exchange) device (Fisher and Paykel Healthcare Ltd, Auckland, New Zealand). Compared to conventional low-flows oxygen therapy systems, the heating and humidification of the flow facilitate tolerability by the patient, ensure an efficient muco-ciliary function and allow to reach higher and more stable inspiratory fractions of oxygen. The system produces a flow-dependent effect of continuous positive airway pressure of about 1 cmH20 for every 10L/min increase in oxygen flow and a reduction of the dead space, having the potential to increase the alveolar volume thus improving gas exchanges. The resulting reduction in respiratory rate and the improvement of thoracoabdominal synchrony minimize the onset of respiratory fatigue in the patient. Initially introduced for the treatment of acute hypoxemic respiratory failure, HFNC oxygen therapy is increasingly used also in anesthesia as the only airways management technique during short-term procedures performed under sedation (e.g. digestive endoscopy) or under general anesthesia (such as microlaryngoscopies). Compared to low-flows oxygen systems, the greater CO2 elimination capacity could reduce the incidence of hypoventilation and apnea episodes potentially associated with patient sedation. Operative hysteroscopy is a brief procedure, normally lasting <30 minutes, usually performed in a day-hospital regime under procedural analgo-sedation, with conventional ventilatory support through a face mask/laryngeal mask. The primary objective of this study is the comparison of the rate of success in airways management via the THRIVE system versus positive pressure ventilation by I-gel laryngeal mask during 180 hysteroscopies performed under general anesthesia. Secondary objectives are: the comparison of intraoperative and postoperative complications between the two groups. Materials and methods Patient monitoring throughout the procedure will include automatic noninvasive, intermittent (every 5 minutes) blood pressure monitoring, 3-leads electrocardiogram, peripheral oxygen saturation (SpO2), bispettral index (BIS), transcutaneous capnography with TCM5 Radiometer monitor. Upon arrival in the operating room, the patient will assume the lithotomic position; a peripheral venous cannula will be placed at the level of the hand or forearm and it will begin the infusion of Ringer Lactate solution 3 ml/kg/h. Omeprazole 40 mg and dexamethasone 4 mg will be administered before the procedure as standard internal practice. In the THRIVE group, dedicated Optiflow THRIVETM nasal cannulas will be positioned for 100% high flow oxygen therapy at an initial flow of 30 L/min. After induction of anesthesia and throughout the procedure the flow of oxygen will be increased to 70 L/min. In the control group (CONTROL) after induction of anesthesia the patient will be mechanically ventilated through an I-Gel laryngeal mask. General anesthesia, as per normal clinical practice, will be induced and maintained by target-controlled infusion (TCI) of propofol (7 mcg/Kg) by Orchestra Infusion system (Fresenius Kabi) and fentanyl 1.5 mcg/kg and in both groups. Propofol infusion rate will be between 3-4 mcg/ml for propofol, so to maintain a level of sedation monitored via BIS between 40-50. Paracetamol 1g, ondansetron 4 mg and ketorolac 30 mg will also be administered as per normal clinical practice. In case of desaturation episodes, defined as a SpO2< 94% or increases in tcCO2 above 65 mmHg, the patient will be assisted with positive pressure ventilation through a facial or laryngeal mask or oro-tracheal intubation based on clinical judgment of the anesthesiologist. At the end of the hysteroscopy the patient will be transferred to the Post-Anesthesia Care Unit (PACU) for 3 hours of post-procedural monitoring as required by internal protocol for day-surgery procedures. Standard monitoring will include non-invasive, intermittent (every 15 minutes) blood pressure monitoring, 3-leads electrocardiogram and peripheral oxygen saturation (SpO2). One hour after the end of the procedure and before discharge from the PACU the patient will be asked to quantify the perceived degree of dyspnea with the Borg dyspnoea score and the degree of comfort using a Visual Numeric Scale (VAS) ranging from 0 to 10. In case of SpO2<94%, additional oxygen will be administered by means of a Venturi-type face mask with FiO2 40%. Discharge from the PACU will require an Aldrete score of 9-10. Statistics The data will be analyzed according to an intention-to-treat principle. Clinical and demographic characteristics of the sample will be described through descriptive statistical techniques. Continuous quantitative variables with normal distribution will be reported as mean and standard deviation; as median and interquartile range the non-normal variables. Categorical variables and missing data will be presented as absolute values and percentage, n (%). Continuous variables will be compared with the Student t-test in case of normal distribution or, if not, with the Mann-Whitney test for independent samples. The normality of the distribution of the variables will be verified graphically by histograms and with the Shapiro-Wilk test. Continuous variables with repeated measurements will be compared with a mixed-effect linear regression model. The type of airway management used and the timing at which the measurements will be performed will be considered as fixed effects; a random effect related to the patient will also be added. The assumption of normality of the residues of the model will be graphically verified by histograms and Q-Q plots. The P-values will be obtained with the likelihood ratio test of the complete model with the effect in question with respect to the model without the effect. The estimates of the predictors used in the model will be reported with the relative 95% confidence intervals and P-values obtained with the Wald test. In case of failure of the technique, defined as a transcutaneous concentration of carbon dioxide (tcCO2) > 60 mmHg and/or SpO2 < 94% in any of the study groups, a time-to-event (Kaplan-Meier) analysis will be carried out that takes into account the different duration of the procedures and therefore the different risk ranges for the possible onset of hypercapnia and / hypoxemia. Differences between categorical data will be reported in terms of relative risk or risk differences, 95% confidence intervals and p-values based on the Χ2 test or fisher's exact test. The significance level will be set for α < 0.05. All analyses will be performed with the statistical software R version 4.1.2 (R Foundation for Statistical Computing, Austria). Continuous variables with repeated measurements will be compared with a mixed-effect linear regression model. Normality of distribution will be verified with the Shapiro-Wilk test. Continuous variables will be compared with Student t - or Mann Whitney test; categorical variables with the Chi-square test. Sample size calculation In 2021, Kim et al. compared the safety of high flow oxygen therapy to conventional low-flow oxygen support for gastrointestinal endoscopic procedures performed under sedation reporting minimum values of peripheral saturation detected by pulse-oximeter higher in the high-flow group (99.8%) compared to low-flow oxygen therapy (95.1%). To our knowledge, no study has compared these two methods during operative hysteroscopies under procedural sedation. Based on literature and on the results from an internal registered pilot study in which we investigated the success rate of THRIVE as unique airway management technique in this setting, assuming a similar success rate of 95% for THRIVE and laryngeal mask ventilation, for a unilateral confidence interval of 95% and a 90% test power, we estimated a minimum sample of 82 patients per group to test a non-inferiority limit of 10%. The sample was increased to 90 patients for group to take into account any dropouts.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometrium; Hypertrophy, Cervix, Anesthesia, Apnea, Postanesthetic
Keywords
High flow nasal cannula Oxygen, Procedural sedation, Apnoeic ventilation, Operative hysteroscopy, THRIVE

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
180 (Actual)

8. Arms, Groups, and Interventions

Arm Title
THRIVE
Arm Type
Experimental
Arm Description
Ventilatory management during surgery provided by transnasal humidified rapid-insufflation ventilatory exchange.
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Ventilatory management during surgery provided by mechanical ventilation through laringeal mask
Intervention Type
Device
Intervention Name(s)
Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE).
Intervention Description
In the THRIVE group, dedicated Optiflow THRIVE nasal cannulas will be positioned for 100% high flow oxygen therapy at an initial flow of 30 L/min. After induction of anesthesia and throughout the procedure the flow of oxygen will be increased to 70 L/min.
Intervention Type
Device
Intervention Name(s)
LMA
Intervention Description
Mechanical ventilation performed by a laringeal mask
Primary Outcome Measure Information:
Title
Rate of success of ventilation with THRIVE.
Description
Comparison of the rate of success in airways management with the THRIVE system versus positive pressure ventilation by laryngeal mask. The failure of the method will be defined as a CO2 value measured by transcutaneous monitor (Radiometer) > 65 mmHg AND/OR a peripheral O2 saturation measured by pulse oximeter < 94%.
Time Frame
Throughout the surgical procedure
Secondary Outcome Measure Information:
Title
Airway related complications.
Description
Comparison of percentage of patients requiring airway manipulations (nasal cannula, manual ventilation, laryngeal mask ventilation, tracheal intubation) by the anesthesiologist in the two groups
Time Frame
At the end of the surgery.
Title
Postoperative complications - 1
Description
Comparison of percentage of patients suffering from cough, sore throat, dysphagia, dysphonia, laryngospasm, oxygen desaturation (defined as SpO2<94%).
Time Frame
At the end of the surgery.
Title
Postoperative complications - 2
Description
Comparison of incidence of dyspnoea (measured with Borg dyspnoea score: 0= no dyspnoea, 10= maximal dyspnoea) in the two groups.
Time Frame
At the end of the surgery.
Title
Postoperative complications - 3
Description
Comparison of incidence of discomfort (measured with Visual Analogue Scale: 0= no discomfort, 10= maximal discomfort) in the two groups.
Time Frame
At the end of the surgery.

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing operative hysteroscopy ASA I-II. Exclusion Criteria: BMI > 30, pregnancy, cardiac arrhythmia, high risk of aspiration, neuromuscular disease, patient refusal.
Facility Information:
Facility Name
IRCCS Fondazione Policlinico A. Gemelli
City
Rome
ZIP/Postal Code
00167
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
13630833
Citation
BARTLETT RG Jr, BRUBACH HF, SPECHT H. Demonstration of aventilatory mass flow during ventilation and apnea in man. J Appl Physiol. 1959 Jan;14(1):97-101. doi: 10.1152/jappl.1959.14.1.97. No abstract available.
Results Reference
result
PubMed Identifier
25388828
Citation
Patel A, Nouraei SA. Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE): a physiological method of increasing apnoea time in patients with difficult airways. Anaesthesia. 2015 Mar;70(3):323-9. doi: 10.1111/anae.12923. Epub 2014 Nov 10.
Results Reference
result
PubMed Identifier
7429910
Citation
O'Cain CF, Dowling NB, Slutsky AS, Hensley MJ, Strohl KP, McFadden ER Jr, Ingram RH Jr. Airway effects of respiratory heat loss in normal subjects. J Appl Physiol Respir Environ Exerc Physiol. 1980 Nov;49(5):875-80. doi: 10.1152/jappl.1980.49.5.875.
Results Reference
result
PubMed Identifier
6808323
Citation
Slutsky AS, Brown R. Cardiogenic oscillations: a potential mechanism enhancing oxygenation during apneic respiration. Med Hypotheses. 1982 Apr;8(4):393-400. doi: 10.1016/0306-9877(82)90032-9.
Results Reference
result
PubMed Identifier
30767199
Citation
Hermez LA, Spence CJ, Payton MJ, Nouraei SAR, Patel A, Barnes TH. A physiological study to determine the mechanism of carbon dioxide clearance during apnoea when using transnasal humidified rapid insufflation ventilatory exchange (THRIVE). Anaesthesia. 2019 Apr;74(4):441-449. doi: 10.1111/anae.14541. Epub 2019 Feb 15.
Results Reference
result
PubMed Identifier
28320364
Citation
Brzek A, Dworrak T, Strauss M, Sanchis-Gomar F, Sabbah I, Dworrak B, Leischik R. The weight of pupils' schoolbags in early school age and its influence on body posture. BMC Musculoskelet Disord. 2017 Mar 21;18(1):117. doi: 10.1186/s12891-017-1462-z.
Results Reference
result
PubMed Identifier
20406507
Citation
Roca O, Riera J, Torres F, Masclans JR. High-flow oxygen therapy in acute respiratory failure. Respir Care. 2010 Apr;55(4):408-13.
Results Reference
result
PubMed Identifier
25869405
Citation
Vourc'h M, Asfar P, Volteau C, Bachoumas K, Clavieras N, Egreteau PY, Asehnoune K, Mercat A, Reignier J, Jaber S, Prat G, Roquilly A, Brule N, Villers D, Bretonniere C, Guitton C. High-flow nasal cannula oxygen during endotracheal intubation in hypoxemic patients: a randomized controlled clinical trial. Intensive Care Med. 2015 Sep;41(9):1538-48. doi: 10.1007/s00134-015-3796-z. Epub 2015 Apr 14.
Results Reference
result
PubMed Identifier
26329355
Citation
Parke RL, Bloch A, McGuinness SP. Effect of Very-High-Flow Nasal Therapy on Airway Pressure and End-Expiratory Lung Impedance in Healthy Volunteers. Respir Care. 2015 Oct;60(10):1397-403. doi: 10.4187/respcare.04028. Epub 2015 Sep 1.
Results Reference
result
PubMed Identifier
27879385
Citation
Chikata Y, Onodera M, Oto J, Nishimura M. FIO2 in an Adult Model Simulating High-Flow Nasal Cannula Therapy. Respir Care. 2017 Feb;62(2):193-198. doi: 10.4187/respcare.04963. Epub 2016 Nov 22.
Results Reference
result
PubMed Identifier
27856714
Citation
Moller W, Feng S, Domanski U, Franke KJ, Celik G, Bartenstein P, Becker S, Meyer G, Schmid O, Eickelberg O, Tatkov S, Nilius G. Nasal high flow reduces dead space. J Appl Physiol (1985). 2017 Jan 1;122(1):191-197. doi: 10.1152/japplphysiol.00584.2016. Epub 2016 Nov 17.
Results Reference
result
PubMed Identifier
28403407
Citation
Gustafsson IM, Lodenius A, Tunelli J, Ullman J, Jonsson Fagerlund M. Apnoeic oxygenation in adults under general anaesthesia using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) - a physiological study. Br J Anaesth. 2017 Apr 1;118(4):610-617. doi: 10.1093/bja/aex036.
Results Reference
result
PubMed Identifier
31584919
Citation
Wong DT, Dallaire A, Singh KP, Madhusudan P, Jackson T, Singh M, Wong J, Chung F. High-Flow Nasal Oxygen Improves Safe Apnea Time in Morbidly Obese Patients Undergoing General Anesthesia: A Randomized Controlled Trial. Anesth Analg. 2019 Oct;129(4):1130-1136. doi: 10.1213/ANE.0000000000003966.
Results Reference
result
PubMed Identifier
32398433
Citation
Mazzeffi MA, Petrick KM, Magder L, Greenwald BD, Darwin P, Goldberg EM, Bigeleisen P, Chow JH, Anders M, Boyd CM, Kaplowitz JS, Sun K, Terrin M, Rock P. High-Flow Nasal Cannula Oxygen in Patients Having Anesthesia for Advanced Esophagogastroduodenoscopy: HIFLOW-ENDO, a Randomized Clinical Trial. Anesth Analg. 2021 Mar 1;132(3):743-751. doi: 10.1213/ANE.0000000000004837.
Results Reference
result
PubMed Identifier
32890016
Citation
Shih CC, Liang PC, Chuang YH, Huang YJ, Lin PJ, Wu CY. Effects of high-flow nasal oxygen during prolonged deep sedation on postprocedural atelectasis: A randomised controlled trial. Eur J Anaesthesiol. 2020 Nov;37(11):1025-1031. doi: 10.1097/EJA.0000000000001324.
Results Reference
result
PubMed Identifier
23737548
Citation
Itagaki T, Okuda N, Tsunano Y, Kohata H, Nakataki E, Onodera M, Imanaka H, Nishimura M. Effect of high-flow nasal cannula on thoraco-abdominal synchrony in adult critically ill patients. Respir Care. 2014 Jan;59(1):70-4. doi: 10.4187/respcare.02480. Epub 2013 Jun 4.
Results Reference
result
PubMed Identifier
32882605
Citation
Kagan I, Hellerman-Itzhaki M, Neuman I, Glass YD, Singer P. Reflux events detected by multichannel bioimpedance smart feeding tube during high flow nasal cannula oxygen therapy and enteral feeding: First case report. J Crit Care. 2020 Dec;60:226-229. doi: 10.1016/j.jcrc.2020.08.005. Epub 2020 Aug 22.
Results Reference
result
PubMed Identifier
31401603
Citation
Coudroy R, Frat JP, Ehrmann S, Pene F, Terzi N, Decavele M, Prat G, Garret C, Contou D, Bourenne J, Gacouin A, Girault C, Dellamonica J, Malacrino D, Labro G, Quenot JP, Herbland A, Jochmans S, Devaquet J, Benzekri D, Vivier E, Nseir S, Colin G, Thevenin D, Grasselli G, Assefi M, Guerin C, Bougon D, Lherm T, Kouatchet A, Ragot S, Thille AW; REVA Network. High-flow nasal oxygen therapy alone or with non-invasive ventilation in immunocompromised patients admitted to ICU for acute hypoxemic respiratory failure: the randomised multicentre controlled FLORALI-IM protocol. BMJ Open. 2019 Aug 10;9(8):e029798. doi: 10.1136/bmjopen-2019-029798.
Results Reference
result
PubMed Identifier
29743098
Citation
Mauri T, Galazzi A, Binda F, Masciopinto L, Corcione N, Carlesso E, Lazzeri M, Spinelli E, Tubiolo D, Volta CA, Adamini I, Pesenti A, Grasselli G. Impact of flow and temperature on patient comfort during respiratory support by high-flow nasal cannula. Crit Care. 2018 May 9;22(1):120. doi: 10.1186/s13054-018-2039-4.
Results Reference
result

Learn more about this trial

High Flow Oxygen During Operative Hysteroscopy.

We'll reach out to this number within 24 hrs